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Abstract: Seven medicinal plants popularly used for treating malaria in West Africa were selected to
assess herb-drug interaction potential through a series of in vitro methods. Fluorescent cytochrome
P450 (CYP) assays were conducted using the recombinant CYP enzymes for CYP1A2, CYP2A6,
CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 to assess the effect of the methanolic extracts
on the metabolic activity of CYPs. Secondly, the inhibitory effect of the extracts was evaluated on
P-glycoproteins (P-gp) using calcein-AM, a fluorescent substrate, in MDCK-II and hMDR1-MDCK-II
cells. The inhibition of P-gp activity was determined as a reflection of increase in calcein-AM uptake.
Additionally, the enzyme induction potential of the extracts was assessed through the modulation
of PXR activity in HepG2 cells transiently transfected with pSG5-PXR and PCR5 plasmid DNA.
Significant inhibition of CYP activity (IC50 < 10 µg/mL) was observed with the following herbs:
A. muricata [CYP2C9, 3A4 and CYP2D6]; M. indica [CYP2C9]; M. charantia [CYP2C9 and CYP2C19];
P. amarus [CYP2C19, CYP2C9 and CYP3A4]; T. diversifolia [CYP2C19 and CYP3A4]. Extracts of four
herbs (P. amarus, M. charantia, T. diversifolia and A. muricata) exhibited significant inhibition of P-gp
with IC50 values (µg/mL) of 17 ± 1, 16 ± 0.4, 26 ± 1, and 24 ± 1, respectively. In addition, four herbs
(A. mexicana, M. charantia, P. amarus and T. diversifolia) showed a >two-fold increase in induction
in PXR activity. These findings suggest that these herbs may be capable of eliciting herb-drug
interactions if consumed in high quantities with concomitant use of conventional therapies.
Keywords: cytochrome P450; drug metabolism; enzyme induction; herb-drug interaction; herbal
medicine; malaria; P-glycoprotein; pregnane-X factor
1. Introduction
Malaria remains one of the leading causes of death in several countries of the world. According
to the 2014 malaria statistics of the World Health Organization (WHO), there is ongoing malaria
transmission in 97 countries and territories around the world, with 3.3 billion people at risk of
infection [1]. Artemisinin-based combination therapy (ACT) has been a mainstay of treatment,
as recommended by the WHO. In resource-poor countries, there is still heavy reliance on traditional
herbal remedies for the treatment of malaria [2]. Additionally, the widespread combination of local
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herbal preparations and antimalarial drugs has been reported [3]. Herb-drug interaction (HDI) is the
most important clinical risk in concomitant herb-drug administrations. HDIs are often pharmacokinetic
in nature, in which case, the presence of the herbal products alters the metabolism and/or transport
of the co-administered drug. Pharmacokinetic HDIs pose more risk to the drugs that have narrow
therapeutic windows [4]. Two extremes of clinical experience are possible—therapy failure due to
enzyme induction that leads to faster drugs clearance, and toxicity as a result of enzyme inhibition and
drug accumulation.
The modulation of major drug metabolizing enzymes, especially cytochrome P450 (CYPs)
and drug transporters such as P-glycoproteins (P-gp), is responsible for most clinically relevant
pharmacokinetic HDI [4,5]. Just like drugs, several herbal products have been shown to be capable
of inhibiting and/or inducing various CYP isoforms and drug transporters. HDI is particularly
undesirable for ACT in malaria therapy, because artemisinins, as well as some other antimalarial drugs,
are prodrugs whose conversion to active metabolites is dependent on CYP [6]. The inhibition of CYP
activity by concomitantly administered herbal products will predispose to therapy failure in malaria
treatment. In addition to the associated morbidity and mortality of such treatment failure, the risk of
resistance to ACT by malaria parasites increases upon sub-therapeutic exposure of the parasites to
ACTs. One of the integral parts of the drug development process is the evaluation of the potential of a
new chemical entity for the potential to cause drug-drug interaction. Similar methodologies, including
the in vitro use of liver enzymes and cell lines, are now employed to evaluate HDI [7]. The results
obtained from such in vitro studies can be employed to predict in vivo and clinical relevance, and the
need for further study.
In this study, seven medicinal herbs used in the treatment of malaria in West Africa were selected
for HDI studies. These include Annona muricata, Argermone mexicana, Kalanchoe pinnata, Mangifera indica,
Momordica charantia, Phyllanthus amarus and Tithonia diversifolia.
Annona muricata Linn. (Annonaceae), known for its edible fruit, is a deciduous terrestrial plant
native to Central America, and is widely found in West Africa and other tropical areas. Infusion of its
leaves is traditionally used in the treatment of malaria and other parasitic infections in West Africa [8,9].
Several phytochemical compounds, including annocacin, muricatacin and isoquinoline alkaloids, have
been isolated from the different morphological parts of A. muricata [10,11]. Crude extracts of the leaves
of A. muricata have shown strong in vitro anti-plasmodial and anti-leishmanial activity [12,13].
Argermone mexicana (Papaveraceae), known as Mexican poppy, is a shrub found naturally
in several countries. Its extracts and decoctions are used as traditional antimalarial remedies in
West Africa. Major compounds isolated that are associated with its antimalarial activity include
allocryptopine, berberine and protopine. Nematicidal compounds, phenolics, and several other
alkaloids have also been isolated, but have not been tested against malaria [14,15]. In a prospective and
dose-escalating clinical trial conducted in Mali in 80 human subjects who had symptoms of malaria
(and P. falciparum parasitaemia >2000/µL), decoctions of A. mexicana showed a 73% adequate clinical
response (ACR) with high tolerability and only minor side effects [16]. In a related comparative study
in 301 patients with uncomplicated malaria, it was found that, after 28 days, second-line antimalarial
treatment was not required for 89% of the patients who took A. mexicana, compared to 95% for the
artesunate-amodiaquine group [17]. These findings have led to official approval of the decoctions
of A. mexicana for the treatment of malaria in Mali, which in most cases are still taken alongside
prescription antimalarial drugs [18].
Kalanchoe pinnata Lam (Crassulaceae) is native throughout Africa, where its leafy preparations are
traditionally used to treat fever and malaria infection, although the anti-malarial principles have
not been definitely determined [19,20]. The extracts of the leaves and bark of Mangifera indica
(Anacardiaceae) are a popular traditional antimalarial remedy in West Africa. The extracts have
been shown to possess a schizontocidal effect during early infection, and have also demonstrated
repository activity [21]. Momordica charantia (Cucurbitaceae) is widely used in the treatment of malaria
in West Africa. It has shown weak anti-plasmodial activity [22]. Exracts of Phyllanthus amarus and
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Tithonia diversifolia are also popular in West Africa for the treatment of malaria and other tropical
diseases [23,24].
With the widespread use of these herbal products in malaria treatment along with the
WHO-backed ACT roll-out, it is estimated that a significant portion of the population continues
to use both the traditional remedies and ACTs together. The aim of the current study was, therefore,
to evaluate the selected medicinal plants traditionally used for malarial treatment in terms of their
HDI potential by investigating their effect on drug metabolizing enzymes (CYPs) and major efflux
transporter (P-gp). In this study, methanolic extracts of the selected herbs were used because of the
solubility of most phytochemicals in methanol, compared to water.
2. Results and Discussion
2.1. Inhibition of CYPs by the Herbal Extracts
A fluorescent CYP assay was conducted using the recombinant CYP test kits for CYP1A2, CYP2A6,
CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The antimalarial herbs exerted inhibitory effects
on the CYP isozymes to varying degrees (with IC50 values ranging from 2 to >100 µg/mL) (Figures 1–7).
The inhibition of CYP3A4 was the most pronounced, as all the seven herbs exerted potent inhibitory
activity against this isoform. CYP2D6 was the least inhibited; only A. muricata and A. Mexicana had
any activity against CYP2D6. The computed IC50 values (Table 1) showed the potency of the extracts
against CYP activity. Low IC50 indicates higher potency of inhibition against the CYPs. A. muricata
had the highest potency for inhibition of CYP2D6, CYP2C19, CYP3A4 and CYP1A2. A. mexicana
displayed only moderate inhibition of CYP3A4, CYP2A6, CYP2D6 and CYP2C19. K pinnata inhibited
CYP3A4, CYP2C19 and CYP2B6. M. indica showed inhibitory activity against all of the tested CYP
isoforms, demonstrating the most potent inhibition against CYP2C9, and the least against CYP2D6.
M. charantia strongly inhibited CYP2C9, CYP2C19, CYP1A2, CYP3A4 and CYP2A6 in that (decreasing)
order. P. amarus had a potent inhibitory effect on all of the enzymes except CYP2D6. Its activity against
CYP3A4, CYP2A6 and CYP2B6 was the most potent of the extracts. This is similar to T. diversifolia,
which inhibited CYP1A2, CYP2C9, CYP2C19 and CYP3A4 strongly, exerted a mild inhibition effect on
CYP2B6 and CYP2A6, and showed no activity against CYP2D6.
Molecules 2017, 22, 2049 3 of 12 
 
With the widespread use of these herbal products in malaria treatment along with the WHO-
backed ACT roll-out, it is estimated that a significant portion of the population continues to use both 
the traditional remedies and ACTs together. The aim of the current study was, therefore, to evaluate 
the selected medicinal plants traditionally used for malarial treatment in terms of their HDI potential 
by investigating their effect on drug metabolizing enzymes (CYPs) and major efflux transporter (P-
gp). In this study, methanolic extracts of the selected herbs were used because of the solubility of 
most phytochemicals in methanol, compared to water. 
2. Results and Discussion 
2.1. Inhibition of CYPs by the Herbal Extracts 
A fluorescent CYP assay was conducted using the recombinant CYP test kits for CYP1A2, 
CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The ant malarial herbs exerted 
inhibitory effects on the CYP isozymes to varying degrees (with IC50 values ranging from 2 to >100 
µg/mL) (Figures 1–7). The i hibition of CYP3A4 was the most pronounced, as all the seven herbs 
ex rted potent inhibitory activity against this isoform. CYP2D6 was the l ast inhibited; only A. 
muricat  and A. Mexicana had any activity against CYP2D6. The co puted IC50 valu s (Table 1) 
showed he potency of the extracts against CYP activity. Low IC50 indicates higher potency of 
inhibi ion ag inst he CYPs. A. murica a had the highest p te cy for i hibition of CYP2D6, CYP2C19, 
CYP3A4 and CYP1A2. A. mexicana displayed only moderate inhibition of CYP3A4, CYP2 6, CYP2D6 
and CYP2C19. K pinnata inhib ted CYP3A4, CYP2C19 and CYP2B6. M. indica showed i i itory 
activity against all of the tested CYP isoforms, demonstrating he most po ent inhibi ion against 
CYP2C9  and the le st against CYP2D6. M. charantia stro gly inhibited CYP2C9, CYP2C19, 1A2, 
CYP3A4 and CYP2A6 in that (decreasing) order. P. amarus had a pote t inhibitory effect on all of the 
enzymes except CYP2D6. Its act v y against CYP3A4, CYP2A6 and CYP2B6 was the mos  potent of the 
extracts. This is similar to T. diversifolia, which inhibited CYP1A2, CYP2C9, CYP2C19 and  
CYP3A4 strongly, exerted a mild inhibition effect on CYP2B6 and CYP2A6, an  showed o activity 
against CYP2D6. 
 
Figure 1. The inhibitory effect of graded concentrations of the extracts of A. muricata on the metabolic 
activity of cytochrome P450 enzymes. 
Annona muricata
Log[Conc] µg/mL
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5
Inh
ibi
tio
n (
%)
-20
0
20
40
60
80
100
CYP1A2
CYP2C19
CYP2D6
CYP3A4
CYP2A6
CYP2B6
CYP2C9
Figure 1. The inhibitory effect of graded concentrations of the extracts of A. muricata on the metabolic
activity of cytochrome P450 enzymes.
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Figure 4. The inhibitory effect of graded concentrations of the extracts of M. indica on the metabolic
activity of cytochrome P450 enzymes.
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activity of cytochrome P450 enzymes.
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Table 1. The inhibitory potency of the selected antimalarial herbs on the activity of CYP enzymes.
Herbs (Part Used) 1A2 2A6 2B6 2C9 2C19 2D6 3A4
IC50 (µg/mL)
Annona muricata
(leaves) 26.1 ± 3.1 - >100 - 2.1 ± 1.5 1.85 ± 3.3 2.2 ± 4.4
Argemone Mexicana
(whole plant) >100 93.1 ± 8.5 >100 - 98.2 ± 9.3 96.1 ± 8.2 55.0 ± 5.1
Kalanchoe pinnata (stem) - >100 96.1 ± 7.7 - 91.2 ± 5.8 - 55.3 ± 7.2
Mangifera indica
(stem bark) 42.2 ± 4.7 47.3 ± 4.1 87.4 ± 8.1 3.3 ± 0.6 32.4 ± 5.1 >100 44.2 ± 3.1
Momordica charantia
(leaves and stem) 23.4 ± 4.3 34.1 ± 3.3 - 3.3 ± 0.5 6.4 ± 1.5 - 31.1 ± 5.2
Phyllanthus amarus
(leaves, root and stem) >100 28.1 ± 2.6 11.2 ± 1.5 5.3 ± 1.1 3.8 ± 1.0 - 0.5 ± 0.2
Tithonia diversifolia
(leaves) 64.3 ± 5.2 >100 98.4 ± 5.5 21.2 ± 2.0 3.8 ± 4.5 - 3.5 ± 2.2
(-) indicates absence of inhibition.
2.2. P-glycoprotein Inhibition
P-gp inhibition was measured by monitoring calcein-AM uptake in transfected hMDR1-MDCKII
cells. Extract concentrations were profiled against % increase in Calcein AM uptake (Figure 8). Extracts
of four of the herbs—P. amarus, M. charantia, T. diversifolia and A. Muricata—exhibited significant
P-gp inhibition with EC50 values (µg/mL) of 17 ± 1.4, 16 ± 0.3, 26 ± 1.1, 24 ± 0.9, respectively.
These findings suggest that the herbal products, if taken in sufficient quantities, may inhibit the activity
of intestinal P-gp and alter the absorption kinetics of its substrates.
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2.3. Pregnane-X Receptor Modulation
The effects of the methanolic extracts of seven antimalarial herbs on PXR were assessed in HepG2
cells. PXR-transfected HepG2 cells were treated with the extracts for 24 h, and the fold increase
in luciferase activity was measured as an index of PXR activation. A fold-increase in induction
of 2 or more in the PXR activity is considered significant (indicating a 100% increase compared to
vehicle control) [25]. Cells treated with methanol and rifampicin served as vehicle and positive
controls, respectively.
As shown in Table 2, three extracts (A. mexicana, M. charantia, and P. amarus) showed >2-fold
increase in induction in PXR activity at a concentration of 20 µg/mL. P. amarus and M. charantia
exhibited the strongest activity (>4 fold) at 60 µg/mL. However, T. diversifolia showed maximal activity
(2.4 fold induction) at a lower concentration (6.67 µg/mL). These results indicate that these four extracts
may significantly modulate the transcriptional activity of PXR, and could thereby affect the expression
of downstream genes involved in PXR signaling. Additionally, no cytotoxicity was observed toward
HepG2 cells.
Table 2. The induction of pregnane X receptor activity and the inhibition of P-glycoprotein by the
extracts of 7 selected plants.
Fold Induction in PXR Activity
Sample/Conc (µg/mL) 60 20 6.67 2.22 0.74
Annona muricata (leaves) 1.66 1.17 1.14 0.89 0.89
Argemone Mexicana (whole plant) 2.50 2.09 1.41 1.33 1.03
Kalanchoe pinnata (stem) - - - - -
Mangifera indica (stem bark) - - - - -
Momordica charantia (leaves and stem) 4.64 2.67 1.67 1.22 1.25
Phyllanthus amarus (leaves, root and stem) 4.71 3.67 2.34 1.44 1.04
Tithonia diversifolia (leaves) - 1.47 2.41 1.74 1.35
(-) indicates absence of induction.
2.4. iscussion
I studies have gained pro inence in recent ti es due to the increasing clinical reports of
herbal products interfering with the effects of drugs concurrently consumed. Failure of contraceptives
due to the inductive effect of St John’s wort or bleeding from warfarin therapy due to the inhibition
of warfarin metabolism by ginkgo are documented examples of clinically significant HDI [26,27].
Not much has been studied in terms of the effect of herbal products on anti-infective drugs. In malaria
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treatment especially, where the utility of existing drugs is threatened by resistant strains of the
parasite, subtherapeutic exposure to the drugs is of great concern. This is particularly so considering
that the major antimalarial drugs—artemisinins (artesunate, arteeter, arthemete), amodiaquine and
primaquine—are prodrugs whose conversion to active metabolites is CYP-dependent. The inhibition
of CYP activity is thus not desirable when these antimalarial drugs are used.
The modulatory activity of artemisinins themselves on drug-metabolizing enzymes have been
reported in previous studies. Artemisinins undergo CYP2B6-medicated autoinduction, an underlying
mechanism that has been used to explain the observed high recrudescence rate associated with
its antimalarial use [28–30]. The molecular mechanism for the interaction of artemisinins with
drug-metabolizing enzymes is its ability to activate PXR and constitutive androstane receptor (CAR).
Thus, drug interactions with artemisinins have been a concern in malaria treatment due to the fact
that most combination drugs are substrates of CYPs [31]. The concurrent use of herbal products will
further increase this risk.
In the present study, several herbs exhibited potent inhibitory effects on CYP2A6, CYP2B6 and
3A4, which are the major isoforms involved in the formation of the active dihydroartemisinin from
the artemisinins. The inhibition of the CYP2C family by all the extracts is also instructive, as this
enzyme family metabolizes amodiaquine to its active metabolite [32]. However, the extent of in vivo
absorption of these herbs is not known, and the current findings suggest that the concomitant use of
the herbs and the antimalarial drugs may be undesirable. The overall bioavailability could be affected
due to the presence of CYP and P-gp in the intestinal mucosa. It may thus be advisable to avoid
concurrent consumption of antimalarial drugs and the implicated antimalarial herbs, in order to avoid
the suppression of the formation of the active metabolites.
P-gp is an important mediator of HDI. In vitro inhibition/induction of P-gp is an important
indicator for HDI because of the abundant expression of P-gp in the intestinal epithelium. This implies
that, regardless of absorption into the systemic circulation, P-gp inhibition can alter the bioavailability
of orally administered drugs. Calcein-AM is a commonly used probe substrates of P-gp [33]. In the
calcein-AM assay, A. muricata, M. charantia, P. amarus and T. diversifolia exhibited significant P-gp
inhibition similar to cyclosporin A, the positive control (Figure 8).
Apart from enzyme/transporter inhibition, the induction of metabolic enzymes/transporters has
been recognized as a common mechanism of HDI. The use of the human PXR-transfected HepG2 cells
as an in vitro tool for evaluating the potential for clinically significant induction of drug-metabolizing
enzymes and transporter proteins is well established [34]. Herbal products including St John’s wort
and ginkgo, known to induce metabolic enzymes and transporter proteins have been shown to be
activators of PXR [35,36]. The ability of A. mexicana, M. charantia, P. amarus, and T. diversifolia to
cause more than a two-fold increase in PXR activity is an indication that they may cause an increased
expression of drug metabolizing enzymes and/or transporter, which is considered a significant factor
that causes HDI [37]. Induction of enzyme activity is usually undesirable, due to increased drug
metabolism and the risk of sub-therapeutic exposure of infective organism to the drug. It is also a risk
for the development of drug resistance.
Further studies, including the determination of the extent of absorption of the active
phytochemicals in the herbs and their interactions in humans, may provide more useful information
which would be helpful in establishing the clinical significance of these findings.
3. Materials and Methods
3.1. Materials
Methanolic extracts of the seven selected herbs (prepared from voucher specimens) were obtained
from the repository of the National Center for Natural Products Research (NCNPR), School of
Pharmacy, University of Mississippi. CYP1A2/CEC, CYP2C9/MFC, CYP2C19/CEC, CYP2D6/AMMC
and CYP3A4/BQ high throughput inhibitor screening kits (containing recombinant human CYPs,
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substrates and relevant buffers systems) were purchased from BD Gentest (Woburn, MA, USA).
Transwell plates (12 mm diameter, 0.4 µM pore size) were purchased from Costar Corp. (Cambridge,
MA, USA). Madin-Darby canine kidney-II (parental) and hMDR1-MDCKII (transfected) cell lines were
a gift from Dr. Gottesman (NIH, Bethesda, MD, USA). Fetal bovine serum (FBS) was purchased from
Hyclone Lab Inc. (Logan, UT, USA). Dulbecco’s Modified Eagle Medium (DMEM), Minimal Essential
Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin streptomycin,
and Sodium Pyruvate were purchased from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).
Troleandomycin was from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). All other chemicals were
from Sigma Chem. Co., (St. Louis, MO, USA).
3.2. Inhibition Assay with Recombinant CYPs
The assay to determine the inhibitory activity of the selected medicinal plants on the metabolic
activity of CYPs was conducted under similar conditions as earlier reported [38,39]. The extracts and
positive controls were serially diluted in a solution (100 µL) of cofactors mix, CYP proteins (0.05 mg of
protein/mL), and G-6-PDH to achieve six concentrations ranging from 0.4 to 100 µg/mL. Methanol
was used as the negative control. Initial readings were taken to record any inherent fluorescence and
the plates were incubated at 37 ◦C for 10 min. Enzymatic reaction was initiated by the addition of
the enzyme substrate mixture (100 µL) followed by incubation for 15, 30, or 45 min (according to the
supplier instructions for each enzyme). The total volume of the incubation mixture was 200 µL in
96-well microplates. The reaction was terminated by the addition of 75 µL of ice cold acetonitrile/0.5 M
Tris base (80:20). Fluorescence was measured on a Spectramax M5 plate reader (Molecular Devices,
Sunnyvale, CA, USA) at specified excitation and emission wavelengths for each substrate. The tested
concentrations were profiled against observed enzyme inhibition (%) in order to obtain the IC50 values
of each extract.
3.3. Assay for P-glycoprotein Inhibition by Calcein-AM Uptake in Parental and Transfected MDCK-II Cells
In order to determine the influence of the extracts on the efflux activity of P-gp, a similar assay
was performed to that previously described [33]. Typically, cells were seeded in 96-well plates at about
70,000 cells/well in 200 µL of culture medium. The medium was changed 24 h after seeding and the
assay was performed 48 h later. Varying concentrations (0.4–100 µg/mL) of the herbal extracts and
the positive control (cyclosporine A 0.4–100 µM) were added to the cells in 50 µL of transport buffer
and incubated at 37 ◦C for 10 min. Methanol was used as the negative control. Calcein-AM (1 µM),
a fluorescent substrate of P-gp, was added and the plates were immediately placed on Spectramax and
fluorescence was read up to 1 h at 15-min intervals at excitation and emission wavelengths of 485 and
530 nm, respectively. Changes in calcein-AM uptake were calculated as described previously [40,41].
The concentration that causeed 50% increase in calcein-AM uptake (IC50) was determined by plotting
the increase (%) in calcein-AM uptake against the log concentration using GraphPad Prism software
V.7.0 (GraphPad Software, Inc., San Diego, CA, USA)
3.4. Assay for PXR Modulation
The PXR modulation assay was performed as previously described [42]. The modulation of
PXR activity by the selected extracts was determined in HepG2 cells transiently transfected with
pSG5-PXR (25 µg) and PCR5 plasmid DNA (25 µg) by electroporation at 180 V, 1 pulse for 70 ms.
The cells were plated in 96-well plates at a density of 50,000 cells per well and left for 24 h before varying
concentrations of extracts and control compounds (including methanol as negative control) were added.
This was followed by 24-h incubation, after which the media was aspirated and 40 µL of luciferase
reagent (Promega Corporation, Madison, WI, USA) was added to each well. The luminescence was
then measured on Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA). The fold
induction in luciferase activity in the treated cells was calculated in comparison to vehicle-treated
cells. The cell viability was determined using the CellTiter 96 AQueous One Solution Cell Proliferation
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Assay (MTS), as described previously as a measure of the cytotoxic effect of the extracts on the HepG2
cells [39].
3.5. Calculation of IC50 Inhibition Values
The activity (100%) of the enzymes/cells was defined in terms of metabolite production/substrate
uptake in the absence of inhibitor (negative controls). The enzyme/calceine uptake inhibition
parameter (IC50) was calculated by using the kinetic equation for sigmoid curves (Equation (1)),
where x = concentration, y = relative enzyme activity, and s = slope factor.
y =
100%
1 +
(
x
IC50
)S (1)
3.6. Statistical Methods
All determinations were performed in triplicate, and values are represented as mean ± SD
(n = 3). Statistical analysis was performed using one-way ANOVA and Dunnett’s multiple comparison
tests with GraphPad Prism Version 5 (San Diego, CA, USA). p < 0.05 was considered to be
statistically significant.
4. Conclusions
The findings from this study have demonstrated that the methanolic extracts of the
following herbs inhibit the indicated CYP enzymes: A. muricata—CYP2C9, 3A4 and CYP2D6;
M. indica—CYP2C9; M. charantia—CYP2C9 and CYP2C19; P. amarus—CYP2C19, CYP2C9 and CYP3A4;
and T. diversifolia—CYP2C19 and CYP3A4. The extracts of P. amarus, M. charantia, T diversifolia and
A. muricata exhibited significant P-gp inhibition. Additionally, A. mexicana, M. charantia, P. amarus,
and T. diversifolia—showed >2-fold induction in PXR activity. By implication, the concomitant use of
products containing these herbs with prescription drugs may pose a risk for HDI. Further studies are
warranted in this regard.
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